| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,033 | -7,394 | -7,921 | -10,000 |
| Depreciation and amortization | 56 | 55 | 54 | 107 |
| Loss on disposal of property and equipment | -1 | 0 | -1 | - |
| Amortization of operating lease right-of-use assets | 94 | 91 | 89 | 171 |
| Unrealized foreign exchange gains | 4 | 3 | 12 | 158 |
| Stock in lieu of debt repayment | - | 0 | 31 | - |
| Stock-based compensation | 334 | 197 | 307 | 322 |
| Bad debt expense | 0 | 0 | 0 | 11 |
| Accounts receivable | -594 | 629 | 16 | -167 |
| Inventory | 504 | -200 | 145 | 413 |
| Prepaid expenses and other current assets | -8 | -129 | -636 | 939 |
| Other long-term assets | 35 | 0 | 0 | 0 |
| Accounts payable | 198 | -220 | 188 | 408 |
| Accrued expenses and other current liabilities | 417 | -92 | 1,201 | 1,019 |
| Deferred revenue | -93 | 71 | 9 | -35 |
| Operating lease liabilities | -99 | -91 | -88 | -172 |
| Net cash used in operating activities | -6,066 | -7,686 | -5,666 | -9,512 |
| Purchases of property and equipment | 48 | 8 | 12 | 70 |
| Net cash used in investing activities | -48 | -8 | -12 | -70 |
| Proceeds from issuance of series h convertible preferred stock | - | 0 | 0 | - |
| Proceeds from ipo, net of commissions | - | 0 | 26,557 | - |
| Payment of ipo offering costs | - | 0 | 3,184 | - |
| Proceeds from promissory note issuance | - | 0 | 0 | 1,000 |
| Proceeds from private placement | 14,000 | - | - | - |
| Repayment of promissory note | - | 0 | 1,000 | - |
| Payment of private placement issuance costs | 87 | - | - | - |
| Proceeds from exercises of options on common stock and warrants | 39 | 15 | 14 | 202 |
| Net cash provided by financing activities | 13,952 | 15 | 22,387 | 1,202 |
| Net increase (decrease) in cash and cash equivalents | 7,838 | -7,679 | 16,709 | -8,380 |
| Effect of exchange rate changes on cash and cash equivalents | -17 | 4 | 139 | - |
| Cash and cash equivalents at beginning of period | 10,112 | 17,787 | 9,319 | - |
| Cash and cash equivalents at end of period | 17,933 | 10,112 | 17,787 | - |
CapsoVision, Inc (CV)
CapsoVision, Inc (CV)